Bicycle Therapeutics (NASDAQ:BCYC – Get Rating) and IMV (NASDAQ:IMV – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, institutional ownership, dividends, profitability and earnings.
Risk & Volatility
Bicycle Therapeutics has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500. Comparatively, IMV has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500.
Insider & Institutional Ownership
76.5% of Bicycle Therapeutics shares are held by institutional investors. Comparatively, 11.4% of IMV shares are held by institutional investors. 9.0% of Bicycle Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings and price targets for Bicycle Therapeutics and IMV, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Bicycle Therapeutics presently has a consensus target price of $52.40, indicating a potential upside of 92.79%. IMV has a consensus target price of $1.50, indicating a potential upside of 447.65%. Given IMV’s higher probable upside, analysts plainly believe IMV is more favorable than Bicycle Therapeutics.
Earnings & Valuation
This table compares Bicycle Therapeutics and IMV’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Bicycle Therapeutics||$11.70 million||68.97||-$66.82 million||($3.42)||-7.95|
IMV has lower revenue, but higher earnings than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than IMV, indicating that it is currently the more affordable of the two stocks.
Bicycle Therapeutics beats IMV on 8 of the 14 factors compared between the two stocks.
About Bicycle Therapeutics
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.